Given the expression of CD74 on monocytes/macrophages and B cells, treatment with milatuzumab may permit combined targeting of the innate and adaptive immune systems and thus may be promising for treating autoimmunity, as exemplified by successful anti-cytokine treatment. This evidence concerns the gene CD74 and Autoimmunity.